Company / R&D per Share
Gilead Sciences R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$4.65
FY2025
5-year range
$3.23 / $4.74
FY2021-FY2025
Trend
-1.8%
vs FY2024
Sector context
#40 of 208
Health Care
What the data says
Gilead Sciences's r&d per share of $4.65 is higher than 81% of companies in the Health Care sector (FY2025). R&D per Share has fluctuated over the past 10 years, ranging from $2.01 in FY2016 to $4.74 in FY2024.
Based on SEC 10-K filings.
4.65 in FY2025 with a 5-year CAGR of +3.6%. Top quartile in the Health Care sector.
Improved from $3.69 to $4.65 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +5.8%
- 5-Year CAGR
- +3.6%
- 10-Year CAGR
- -
Sector benchmark
Top 19% in Health CareTop 19% of 208This company $4.65 Sector average $28.82
▼
-83.9% below sector average
Key checks
Key Insights
- In FY2025, r&d per share decreased 1.8% year-over-year.
- Ranks #40 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2024.
- Lowest r&d per share in the period was in FY2016.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.65 | -1.8% |
| FY2024 | $4.74 | +28.5% |
| FY2023 | $3.69 | -6.1% |
| FY2022 | $3.93 | +21.5% |
| FY2021 | $3.23 | -16.9% |
| FY2020 | $3.89 | +33.6% |
| FY2019 | $2.91 | -25.3% |
| FY2018 | $3.90 | +69.4% |
| FY2017 | $2.30 | +14.6% |
| FY2016 | $2.01 | -0.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026